Management of stage III non–small-cell lung cancer: ASCO guideline
ME Daly, N Singh, N Ismaila, MB Antonoff… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …
Revisiting neoadjuvant therapy in non-small-cell lung cancer
Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …
SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non–small-cell lung cancer—a multicenter single-arm phase II trial
SI Rothschild, A Zippelius, EI Eboulet… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE For patients with resectable stage IIIA (N2) non–small-cell lung cancer,
neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1 …
neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1 …
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …
[HTML][HTML] Scientific advances in lung cancer 2015
AS Tsao, GV Scagliotti, PA Bunn Jr, DP Carbone… - Journal of Thoracic …, 2016 - Elsevier
Lung cancer continues to be a major global health problem; the disease is diagnosed in
more than 1.6 million new patients each year. However, significant progress is underway in …
more than 1.6 million new patients each year. However, significant progress is underway in …
[HTML][HTML] Therapeutic management options for stage III non-small cell lung cancer
SM Yoon, T Shaikh, M Hallman - World journal of clinical oncology, 2017 - ncbi.nlm.nih.gov
Lung cancer is the leading cause of cancer death worldwide. Majority of newly diagnosed
lung cancers are non-small cell lung cancer (NSCLC), of which up to half are considered …
lung cancers are non-small cell lung cancer (NSCLC), of which up to half are considered …
[HTML][HTML] Current status and future perspectives on neoadjuvant therapy in lung cancer
GM Blumenthal, PA Bunn Jr, JE Chaft… - Journal of Thoracic …, 2018 - Elsevier
Abstract This Review Article provides a multi-stakeholder view on the current status of
neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and …
neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and …
The current treatment landscape in the UK for stage III NSCLC
M Evison, AstraZeneca UK Limited - British journal of cancer, 2020 - nature.com
For stage III non-small cell lung cancer (NSCLC), approximately a third of patients survive up
to 5 years, with decreasing 5-year survival rates for stage IIIB and stage IIIC disease …
to 5 years, with decreasing 5-year survival rates for stage IIIB and stage IIIC disease …
A critical review of recent developments in radiotherapy for non-small cell lung cancer
S Baker, M Dahele, FJ Lagerwaard, S Senan - Radiation oncology, 2016 - Springer
Lung cancer is the leading cause of cancer mortality, and radiotherapy plays a key role in
both curative and palliative treatments for this disease. Recent advances include stereotactic …
both curative and palliative treatments for this disease. Recent advances include stereotactic …
[HTML][HTML] Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
W Liang, K Cai, C Chen, H Chen, Q Chen… - … lung cancer research, 2020 - ncbi.nlm.nih.gov
Lung cancer is the leading cause of cancer-related death worldwide and in China (1).
According to the statistics of the National Cancer Center of China, there were 733,300 new …
According to the statistics of the National Cancer Center of China, there were 733,300 new …